{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:14:46Z","timestamp":1789456486655,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04174-9","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:00:29Z","timestamp":1788397229000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of pharmacokinetically guided and body surface area\u2013based 5-fluorouracil dosing in colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Maryam","family":"Saqib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9811-7754","authenticated-orcid":false,"given":"Wajahat","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Tahira","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Farooq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mubashra","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundas","family":"Rauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Emam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"4","key":"4174_CR1","first-page":"263","volume":"11","author":"O Capitain","year":"2012","unstructured":"Capitain O, Asevoaia A, Boisdron-Celle M, Poirier AL, Morel A, Gamelin E (2012) Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. Clin Colorectal Cancer 11(4):263\u2013267","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"4174_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2174\/1389557519666191011154923","volume":"20","author":"R Deng","year":"2020","unstructured":"Deng R, Shi L, Zhu W, Wang M, Guan X, Yang D, Shen B (2020) Pharmacokinetics-based dose management of 5-fluorouracil clinical research in advanced colorectal cancer treatment. Mini-Reviews Med Chem 20(2):161\u2013167","journal-title":"Mini-Reviews Med Chem"},{"issue":"13","key":"4174_CR3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","volume":"26","author":"E Gamelin","year":"2008","unstructured":"Gamelin E, Delva R, Jacob J, Merrouche Y, Raoul JL, Pezet D et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26(13):2099\u20132105","journal-title":"J Clin Oncol"},{"issue":"2","key":"4174_CR4","first-page":"119","volume":"13","author":"CL Kline","year":"2014","unstructured":"Kline CL, Schiccitano A, Zhu J, Beachler C, Sheikh H, Harvey HA et al (2014) Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. Clin Colorectal Cancer 13(2):119\u2013126","journal-title":"Clin Colorectal Cancer"},{"key":"4174_CR5","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.929474","volume":"27","author":"X Zhou","year":"2021","unstructured":"Zhou X, Chang Y, Qian J, Shen C, Han J, Zhao H, Chang R (2021) Clinical benefit of therapeutic drug monitoring in colorectal cancer patients who received fluorouracil-based chemotherapy. Med Sci Monit 27:e929474","journal-title":"Med Sci Monit"},{"issue":"3","key":"4174_CR6","first-page":"203","volume":"10","author":"J Saam","year":"2011","unstructured":"Saam J, Critchfield GC, Hamilton SA, Roa BB, Wenstrup RJ, Kaldate RR (2011) Body surface area-based dosing of 5-fluorouracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens. Clin Colorectal Cancer 10(3):203\u2013206","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4174_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/FTD.0000000000000238","volume":"38","author":"R Yang","year":"2016","unstructured":"Yang R, Zhang Y, Zhou H, Zhang P, Yang P, Tong Q et al (2016) Individual 5-fluorouracil dose adjustment via pharmacokinetic monitoring versus conventional body-area-surface method: a meta-analysis. Ther Drug Monit 38(1):79\u201386","journal-title":"Ther Drug Monit"},{"issue":"3","key":"4174_CR8","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1634\/theoncologist.2011-0357","volume":"17","author":"RR Kaldate","year":"2012","unstructured":"Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL (2012) Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist 17(3):296\u2013302","journal-title":"Oncologist"},{"issue":"9","key":"4174_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","volume":"19","author":"JN Patel","year":"2014","unstructured":"Patel JN, O\u2019Neil BH, Deal AM, Ibrahim JG, Sherrill GB, Olajide OA et al (2014) A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. Oncologist 19(9):959\u2013965","journal-title":"Oncologist"},{"issue":"2","key":"4174_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101201","volume":"8","author":"M Li","year":"2023","unstructured":"Li M, Mindt S, L\u00fcck A, Hutzschenreuter U, Kollendt M, Lathan B et al (2023) Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy: results of a prospective, multicenter German observational study. ESMO Open 8(2):101201","journal-title":"ESMO Open"},{"key":"4174_CR11","unstructured":"Covidence systematic review software Veritas Health Innovation, Melbourne, Australia. Available from: www.covidence.org"},{"issue":"3","key":"4174_CR12","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/cpt.1124","volume":"105","author":"JH Beumer","year":"2019","unstructured":"Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R et al (2019) Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology recommendations for 5-fluorouracil therapy. Clin Pharmacol Ther 105(3):598\u2013613. https:\/\/doi.org\/10.1002\/cpt.1124","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4174_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78(3):447\u2013464","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4174_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/FTD.0000000000000701","volume":"42","author":"CE Knezevic","year":"2020","unstructured":"Knezevic CE, Clarke W (2020) Cancer chemotherapy: the case for therapeutic drug monitoring. Ther Drug Monit 42(1):6\u201319","journal-title":"Ther Drug Monit"},{"issue":"4","key":"4174_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.15386\/mpr-2643","volume":"96","author":"AL Deac","year":"2023","unstructured":"Deac AL, Pop RM, Burz CC, Boc\u015fan IC, Militaru C, Suciu \u015e, Buzoianu AD (2023) 5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population. Med Pharm Rep 96(4):413\u2013420","journal-title":"Med Pharm Rep"},{"issue":"10","key":"4174_CR16","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.3390\/cancers18101673","volume":"18","author":"N Sakuyama","year":"2026","unstructured":"Sakuyama N, Nagayasu K, Abe Y, Ochiai T, Shibasaki F (2026) Plasma 5-fluorouracil exposure, clinical outcomes, and therapeutic drug monitoring in advanced colorectal cancer. Cancers 18(10):1673","journal-title":"Cancers"},{"issue":"2","key":"4174_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1055\/s-0043-1776294","volume":"45","author":"PS Nirojini","year":"2024","unstructured":"Nirojini PS, Bhuvaneshwari NK, Dharsshini N, Bharathi SD, Velavan K (2024) Therapeutic drug monitoring of 5-fluorouracil in head and neck cancer patients: an interventional pilot study. Indian J Med Pediatr Oncol 45(2):134\u2013141","journal-title":"Indian J Med Pediatr Oncol"},{"key":"4174_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2024.124424","volume":"1251","author":"M Ando","year":"2025","unstructured":"Ando M, Watanabe N, Seike R, Gocho S, Maeda S, Inagaki M, Kawahara M (2025) Quantification of gimeracil, tegafur, and 5-FU in human plasma via LC-MS\/MS with a simplified pretreatment using flow-through extraction. J Chromatogr B Anal Technol Biomed Life Sci 1251:124424","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"4174_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.snb.2023.135017","volume":"401","author":"M Zouari","year":"2024","unstructured":"Zouari M, Barderas R, Pingarron JM, Raouafi N, Campuzano S (2024) First electrochemical bioplatform to assist in personalized 5-fluorouracil chemotherapy. Sens Actuators B Chem 401:135017","journal-title":"Sens Actuators B Chem"},{"issue":"7","key":"4174_CR20","first-page":"780","volume":"5","author":"LB DeRidder","year":"2024","unstructured":"DeRidder LB, Hare KA, Lopes A, Jenkins J, Fitzgerald N, MacPherson E et al (2024) Closed-loop automated drug infusion regulator: a clinically translatable, closed-loop drug delivery system for personalized drug dosing. Med (Baltimore) 5(7):780\u2013796","journal-title":"Med (Baltimore)"},{"issue":"7","key":"4174_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40262-026-01645-1","volume":"65","author":"Z Tan","year":"2026","unstructured":"Tan Z, Sancho-Araiz A, V\u00f6ller S, Peeters SLJ, Manten T, Deenen MJ et al (2026) Advancing precision dosing of 5-FU: population pharmacokinetic model development, limited sampling strategies, and fit-for-use application. Clin Pharmacokinet 65(7):1027\u20131042. https:\/\/doi.org\/10.1007\/s40262-026-01645-1","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4174_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2017.02.008","volume":"44","author":"M Boisdron-Celle","year":"2017","unstructured":"Boisdron-Celle M, Capitain O, Faroux R, Borg C, Metges JP, Galais MP et al (2017) Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach. Semin Oncol 44(1):13\u201323","journal-title":"Semin Oncol"},{"issue":"12","key":"4174_CR23","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/17425255.2018.1550484","volume":"14","author":"F Goirand","year":"2018","unstructured":"Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC et al (2018) How can we best monitor 5-FU administration to maximize benefit to risk ratio? Expert Opin Drug Metab Toxicol 14(12):1303\u20131313","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4174_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clinbiochem.2018.04.001","volume":"56","author":"OV Neto","year":"2018","unstructured":"Neto OV, Raymundo S, Franzoi MA, do Carmo Artmann A, Tegner M, M\u00fcller VV et al (2018) DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity. Clin Biochem 56:18\u201325","journal-title":"Clin Biochem"},{"issue":"1","key":"4174_CR25","doi-asserted-by":"publisher","first-page":"9711","DOI":"10.1038\/s41598-017-09859-x","volume":"7","author":"P Gokare","year":"2017","unstructured":"Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS (2017) P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase targeting. Sci Rep 7(1):9711","journal-title":"Sci Rep"},{"issue":"2","key":"4174_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101204","volume":"8","author":"I Baraibar","year":"2023","unstructured":"Baraibar I, Ros J, Saoudi N, Salv\u00e0 F, Garc\u00eda A, Castells MR et al (2023) Sex and gender perspectives in colorectal cancer. ESMO Open 8(2):101204","journal-title":"ESMO Open"},{"issue":"11","key":"4174_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3390\/jpm15110516","volume":"15","author":"M Zari\u0107","year":"2025","unstructured":"Zari\u0107 M, \u010canovi\u0107 P, \u017divkovi\u0107 Zari\u0107 R, Protrka S, Gli\u0161i\u0107 M (2025) The three musketeers in cancer therapy: pharmacokinetics, pharmacodynamics and personalised approach. J Personalized Med 15(11):516","journal-title":"J Personalized Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04174-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04174-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04174-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:38Z","timestamp":1789454858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04174-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04174-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"23 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study was a systematic review and meta-analysis of previously published studies and did not involve the direct recruitment of human participants, patient contact, or the use of identifiable data at the individual patient level.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was registered in PROSPERO (registration number: CRD420261417915).","order":3,"name":"Ethics","label":"PROSPERO registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"242"}}